Register for our free email digests:
Latest From LifeCodexx AG
The recent launch of several noninvasive gene-based tests for Down syndrome and other fetal chromosomal abnormalities is poised to upend current prenatal screening practices and potentially usher in a new, multibillion-dollar market opportunity in the process. These new tests employ next-generation gene sequencing, along with advanced, risk-based computer algorithms, to detect and characterize fetal genetic abnormalities using the DNA present in a maternal blood sample. And because they are actually able to “interrogate” the DNA, they represent a huge technological advance over the current standard-of-care for prenatal screening.
- Monitoring Equipment & Devices
- Drug Delivery
- Therapeutic Areas
- Renal System
- Respiratory, Pulmonary
- INO Therapeutics LLC
- North America
- Parent & Subsidiaries
- Ikaria Inc.
- Senior Management
Daniel Tasse, Chmn. & CEO
Tasos G Konidaris, EVP, CFO & Corp. Dev.
Douglas Greene, MD, EVP, CSO
Stephen Ross, EVP, Chief Commerical Officer
- Contact Info
Phone: (908) 238-6600
Perryville III Corp. Pk. 53 Frontage Rd.
P.O. Box 9001 Hampton, NJ 08827-9001
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.